Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL29690831 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3841967 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL29374222 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3885286 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL30244837 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3856872 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137619 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137618 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023230308-A1 | DEGRADER COMPOUNDS OF QSOX1 mRNA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-115707683-A | Method for preparing sertraline intermediate | 浙江华海药业股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| WO-2022257981-A1 | USE OF COMPOUNDS IN INHIBITING OR KILLING MITES AND TREATING DRY-EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| EP-3068793-B1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10842794-B2 | Use of Sigma-1 receptor agonist compounds | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2020-11-24 | — | — | US | disclosed |
| EP-3712128-A1 | PHOTOCHEMICAL INTERMOLECULAR AMINATION METHOD | Fundació Institut Català d'Investigació Química (ICIQ) (ES) | 2020-09-23 | — | — | EP | disclosed |
| WO-2019204764-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190209575-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SigmaDrugs Kft. (HU) | 2019-07-11 | — | — | US | disclosed |
| US-20090062399-A1 | DEUTERIUM-ENRICHED SERTRALINE | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080269306-A1 | Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor | ALPHA 2 PHARMACEUTICA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080153808-A1 | ALPHA-2 RECEPTOR PAN AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
| US-20070260090-A1 | Highly Steroselective Synthesis of Sertraline | HETERO DRUGS LIMITED (IN) | 2007-11-08 | — | — | US | disclosed |
| US-20070260090-A1 | Highly Steroselective Synthesis of Sertraline | HETERO DRUGS LIMITED (IN) | 2007-11-08 | — | — | US | disclosed |
| WO-2007119247-A2 | IMPROVED MANUFACTURING PROCEDURE FOR THE PREPARATION OF POLYMORPHIC FORM II OF CIS-(1S)-N-METHYL-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHLENEAMINE HYDROCHLORIDE (SERTRALINE HYDROCHLORIDE) | UNICHEM LABORATORIES LIMITED (IN) | 2007-10-25 | — | — | WO | disclosed |
| US-20030013768-A1 | Process for the production of sertraline and intermediates useful therefor | ORION COPRORATION FERMION (FI) | 2003-01-16 | — | — | US | disclosed |
| US-20030013768-A1 | Process for the production of sertraline and intermediates useful therefor | ORION COPRORATION FERMION (FI) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260090-A1 | Highly Steroselective Synthesis of Sertraline | HTR3A, TPH1, TPH2 | SLC6A4 22/4885MEN1 1442/4885KMT2A 1649/4885 |
| US-20190209575-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRK1 | SLC6A4 532/4885MEN1 4847/4885KMT2A 3748/4885 |
| US-20030013768-A1 | Process for the production of sertraline and intermediates useful therefor | HTR4, TPH1, HTR1B | SLC6A4 12/4885MEN1 554/4885KMT2A 1555/4885 |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | SERPINA2, FABP1, TTR | SLC6A4 4188/4885MEN1 3457/4885KMT2A 4403/4885 |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | SERPINA2, FABP1, TTR | SLC6A4 4188/4885MEN1 3457/4885KMT2A 4403/4885 |
| US-10842794-B2 | Use of Sigma-1 receptor agonist compounds | SIGMAR1, TMEM97, OPRK1 | SLC6A4 444/4885MEN1 4775/4885KMT2A 4120/4885 |
| US-20080269306-A1 | Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor | SLC6A4, SLC6A2, HTR5A | SLC6A4 1/4885MEN1 4366/4885KMT2A 2342/4885 |
| US-20080153808-A1 | ALPHA-2 RECEPTOR PAN AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | OPRL1, ADRA2A, ADRA2C | SLC6A4 51/4885MEN1 4535/4885KMT2A 2236/4885 |
| US-20090062399-A1 | DEUTERIUM-ENRICHED SERTRALINE | SLC6A4, TPH1, HTR5A | SLC6A4 1/4885MEN1 3065/4885KMT2A 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.